Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. T…
Biotechnology
US, Waltham [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Apellis Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | -4.9800 | -5.846 | 0 | 98 | -309 | -693 | -282 | -55 | -576 | -55 | 67 | 180 |
| 2021 | -4.5900 | -8.701 | 250 | 15 | -344 | -488 | -209 | -443 | -213 | -337 | 139 | 27 |
| 2022 | -8.8400 | -6.267 | 66 | 76 | -746 | -578 | -533 | -554 | -536 | -449 | 176 | 140 |
| 2023 | -6.1500 | -4.485 | 75 | 390 | -652 | -528 | -584 | -610 | -594 | -493 | 277 | 202 |
| 2024 | -4.4500 | -1.321 | 396 | 783 | -528 | -156 | -515 | -444 | -517 | -445 | 499 | 1,433 |
| 2025 | - | 0.136 | - | 1,002 | - | -10 | - | -568 | - | -569 | - | 1,834 |
| 2026 | - | 2.031 | - | 1,349 | - | 2.F6X/td> | - | 2.F61/td> | - | 2.F61 | - | 2.F61 |
| 2027 | - | 3.015 | - | 1,513 | - | 1.F7X/td> | - | 1.F71/td> | - | 1.F71 | - | 1.F71 |
| 2028 | - | 4.172 | - | 1,754 | - | 0.F8X/td> | - | 0.F81/td> | - | 0.F81 | - | 0.F81 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
Overweight
Prev. Grade
Equal-Weight
Nov. 6, 2024
Overweight
Citigroup
1Y Ago:
Underweight
Prev. Grade
Underweight
Nov. 6, 2024
Underweight
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-95.669% $26.51 · MISS
Nov. 6, 2024Price Then
$28.08
Price Target
$54.22
Price Now
$27.71